Bolt presents immune-stimulating antibody-drug conjugate

Nov. 14, 2024

Claudin (CLDN) 18.2 is a transmembrane tight junction protein overexpressed in multiple cancers, including gastric, esophageal and pancreatic cancers.

3D illustration of human digestive system

Immuno-oncology

Bolt Biotherapeutics unveils Claudin 18.2-targeting ISAC candidate

May 15, 2024

Bolt Biotherapeutics Inc. has unveiled BDC-4182, a next-generation Boltbody immune-stimulating antibody conjugate (ISAC) clinical candidate targeting Claudin 18.2.

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...